Drug intelligence / Profile preview

XPF-005

Development stage: Phase 2
Lead developer: Xenon Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

XPF-005 is a small molecule drug developed for topical administration, primarily investigated for the treatment of acne vulgaris. Its precise mechanism of action remains unknown. The compound has reached Phase 2 clinical trials for acne vulgaris but has not been approved in any country and does not have an FDA designation. The active ingredient in XPF-005 is also referred to as XEN801. The developer associated with this drug is Xenon.

Beyond the preview

Go deeper on XPF-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XPF-005.

Explore the full profile